Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05709821
Title IMM60 and Pembrolizumab in Melanoma and NSCLC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors iOx Therapeutics
Age Groups: adult | senior
Covered Countries USA | GBR | ESP

Additional content available in CKB BOOST